trans-Vaccenic acid

Name: trans-Vaccenic acid
Brand: MedChemExpress
SKU: HY-113427
Rating: 4.5 (1 reviews)

Cat. No.: HY-113427 Purity: ≥98.0%: Data Sheet
SDS

COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity.

For research use only. We do not sell to patients.

trans-Vaccenic acid Chemical Structure

CAS No. : 693-72-1

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 68	In-stock	Estimated Time of Arrival: April 11
Solution
10 mM * 1 mL in DMSO	USD 72	In-stock	Estimated Time of Arrival: April 11
Solid
5 mg	USD 65	In-stock	Estimated Time of Arrival: April 11
10 mg	USD 100	In-stock	Estimated Time of Arrival: April 11
25 mg	USD 180	In-stock	Estimated Time of Arrival: April 11
50 mg		Get quote
100 mg		Get quote

Get it by tomorrow April 11 for select sizes. Order within 9 hrs 19 mins.

or Bulk Inquiry

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of trans-Vaccenic acid:

cis-Vaccenic acid Get quote
trans-Vaccenic acid-d₁₃ Get quote
11(E)-Vaccenate sodium Get quote
trans-Vaccenic acid (Standard) Get quote

1 Publications Citing Use of MCE trans-Vaccenic acid

•Int J Biol Macromol. 2024 Oct 1:135992. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

trans-Vaccenic acid is reduced in the rumen to form stearic acid or is desaturated by Δ9-desaturase in the mammary tissue to produce cis-9, trans-11 C18:2, which is an abundant conjugated Linoleic acid isomer in meat and milk^[1].
trans-Vaccenic acid (0-200 μM; 24 h) inhibits NPC cell viability in a dose-dependent manner^[2].
trans-Vaccenic acid (25-100 μM; 24 h) induces apoptosis in NPC cells in a dose-dependent manner. trans-Vaccenic acid significantly increases the levels of cleaved PARP and cleaved caspase-3 in a time-dependent manner^[2].
trans-Vaccenic acid (25-100 μM; 24 h) induces apoptosis in NPC cells through Akt and bad inactivation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	The human NPC cell lines 5-8F and CNE-2
Concentration:	0 μM, 25 μM, 50 μM, 100 μM, 200 μM
Incubation Time:	24 h
Result:	The growth inhibitory ratios of 5-8F cells treated with 25, 50, 100 and 200 μM were 10.8, 18.9, 49.3 and 80.2%, respectively, and those of CNE-2 cells were 7.9, 15.2, 45.3 and 70.5%, respectively.

Apoptosis Analysis^[2]

Cell Line:	The human NPC cell lines 5-8F and CNE-2
Concentration:	25 μM, 50 μM, 100 μM
Incubation Time:	24 h
Result:	Incubation of 5-8F cells with 25, 50 or 100 μM for 24 h caused 7.67, 12.9% or 35% increases in total apoptosis, respectively. Similarly, after incubation with 25 50 or 100 μM CNE-2, the percentage of apoptotic cells was increased by 12.9, 15.1% or 22.3%, respectively. Significantly increased the levels of cleaved PARP and cleaved caspase-3 in a time-dependent manner.

Western Blot Analysis^[2]

Cell Line:	The human NPC cell lines 5-8F and CNE-2
Concentration:	25 μM, 50 μM, 100 μM
Incubation Time:	24 h
Result:	Induced a decrease in Bad phosphorylation on Ser-136 and Ser-112 in a concentration-dependent manner. Protein kinases such as Akt phosphorylate Bad at Ser136, thereby blocking Bad-induced apoptosis. The expression levels of p-Akt were significantly reduced in a dose-dependent manner.

In Vivo

trans-Vaccenic acid (1% w/w; diet; for 8 weeks) alleviates features of metabolic syndrome (MetS) potentially by remodeling adipose tissue and attenuating ectopic lipid accumulation in a rat model of obesity and MetS^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Obese JCR:LA-cp rats^[3].
Dosage:	1% w/w
Administration:	Diet; for 8 weeks
Result:	Reduced total body fat and decreased adipocyte size. Increased metabolic rate concomitantly with an increased preference for whole-body glucose utilization for oxidation and increased insulin sensitivity. Decreased nonalcoholic fatty liver disease activity scores and reduced hepatic and intestinal triglyceride secretion, while exerting differential transcriptional regulation of SREBP1 and FAS amongst other key genes in the liver and the intestine.

Molecular Weight

282.46

Formula

C₁₈H₃₄O₂

CAS No.

693-72-1

Appearance

Solid

Color

White to off-white

SMILES

CCCCCC/C=C/CCCCCCCCCC(O)=O

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Animals

Endogenous metabolite

the fat of ruminants and in human dairy products

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (354.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5403 mL	17.7016 mL	35.4032 mL
5 mM	0.7081 mL	3.5403 mL	7.0806 mL
10 mM	0.3540 mL	1.7702 mL	3.5403 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.85 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil
Solubility: 50 mg/mL (177.02 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, PEG300/PEG400, Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (238 KB)HNMR (191 KB)

Handling Instructions (2659 KB)

References

[1]. Li D, et al. Ruminal microbe of biohydrogenation of trans-vaccenic acid to stearic acid in vitro. BMC Res Notes. 2012 Feb 15;5:97. [Content Brief]

[2]. Song J, et al. Trans-vaccenic acid inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells via a mitochondrial-mediated apoptosis pathway. Lipids Health Dis. 2019 Feb 9;18(1):46. [Content Brief]

[3]. Jacome-Sosa MM, et al. Diets enriched in trans-11 vaccenic acid alleviate ectopic lipid accumulation in a rat model of NAFLD and metabolic syndrome. J Nutr Biochem. 2014 Jul;25(7):692-701. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5403 mL	17.7016 mL	35.4032 mL	88.5081 mL
	5 mM	0.7081 mL	3.5403 mL	7.0806 mL	17.7016 mL
	10 mM	0.3540 mL	1.7702 mL	3.5403 mL	8.8508 mL
	15 mM	0.2360 mL	1.1801 mL	2.3602 mL	5.9005 mL
	20 mM	0.1770 mL	0.8851 mL	1.7702 mL	4.4254 mL
	25 mM	0.1416 mL	0.7081 mL	1.4161 mL	3.5403 mL
	30 mM	0.1180 mL	0.5901 mL	1.1801 mL	2.9503 mL
	40 mM	0.0885 mL	0.4425 mL	0.8851 mL	2.2127 mL
	50 mM	0.0708 mL	0.3540 mL	0.7081 mL	1.7702 mL
	60 mM	0.0590 mL	0.2950 mL	0.5901 mL	1.4751 mL
	80 mM	0.0443 mL	0.2213 mL	0.4425 mL	1.1064 mL
	100 mM	0.0354 mL	0.1770 mL	0.3540 mL	0.8851 mL